Please assess the completion status of the following clinical trial:

Trial Title: Treating Parents to Reduce NICU Transmission of Staphylococcus Aureus Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Neonate has never had a clinical or surveillance culture grow S. aureus~* Neonate was transferred from another hospital or admitted from home and had admission screening cultures for S. aureus colonization that were negative (if admission cultures were not performed, the cultures will be performed as part of the pre-randomization screening process)~* Parent(s) is(are) able to visit the child at the bedside~* Parent(s) test positive for S. aureus at screening~* Neonate has anticipated stay longer than 5 days in the NICU (if estimated stay is unclear, parents can be screened for S. aureus colonization and decision to randomize can be delayed until hospital day 3 or 4 after reassessment of anticipated stay).~* Parents is(are) willing to be randomized~* No documented or reported allergies to any agent used in either treatment regimen~* Able to perform written informed consent~Exclusion Criteria:~* Allergies to any agent used in either treatment regimen~* Neonate has had a prior clinical or surveillance culture grow S. aureus~* Neonate admitted to NICU from home and is greater than 7 days of age~* Neonate admitted to NICU from another hospital and is greater than 7 days of age~* Neonate is a ward of the State~* Not able to provide written informed consent

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Mupirocin and Chlorhexidine (Type: ACTIVE_COMPARATOR): Participants will apply 2% intranasal mupirocin twice a day for five days and cleanse with 2% chlorhexidine cloths once a day for five days.
- Placebo ointment and placebo cloths (Type: PLACEBO_COMPARATOR): Participants will apply 2% petrolatum intranasal placebo ointment twice a day for five days and cleanse with 2% non-medicated soap placebo cloths once a day for five days.

Based on this trial design, predict the completion outcome and termination type (if applicable).